New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
11:11 EDTDGX, GHDX, QGEN, MYGN, LH, ILMNPiper sees ASCO positive for Myriad, Genomic, Illumina at Piper Jaffray
Piper Jaffray said it views the American Society of Clinical Oncology conference as positive for Myriad Genetics (MYGN), Genomic Health (GHDX) and Illumina (ILMN), neutral for QIAGEN (QGEN), and neutral-to-negative for Quest Diagnostics (DGX) and LabCorp (LH). Piper notes traffic for Quest and LabCorp booths was lower than Myriad, which it called the "clear winner" among the BRCA test providers.
News For MYGN;GHDX;ILMN;QGEN;DGX;LH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 22, 2015
12:34 EDTDGX, LHOn The Fly: Top stock stories at midday
Subscribe for More Information
12:10 EDTDGX, LHQuest declines comment to Bloomberg on takeover speculation
Quest Diagnostics (DGX) declined comment to Bloomberg regarding the takeover speculation that pushed the company's stock higher today. Shares of Quest are up $7.01 to $80.89 in midday trading. Shares spiked earlier in the trading day amid talk among traders that Quest hired an investment bank to explore a sale after being approached by a suitor. The talk is unconfirmed speculation that has not been reported by any news agencies. Quest peer LabCorp (LH) is up $1.74 to $122.10 at midday.
10:46 EDTLHLabCorp volatility increases
Subscribe for More Information
10:43 EDTDGX, LHQuest Diagnostics jumps amid takeover speculation
The move higher in Quest Diagnostics (DGX), which was earlier halted for volatility and remains up 15% to $85 per share in morning trading, has been attributed to takeover speculation. Peer Lab Corp. (LH) is also up 3.9% to $125 in morning trading.
10:19 EDTDGXQuest Diagnostics calls active on renewed takeover chatter
Quest Diagnostics June 75 and 80 calls are active on total call volume of 2,100 contracts (100 puts) on renewed takeover chatter. June call option implied volatility is at 18, July is at 19; compared to its 26-week average of 19. Active call volume suggests traders taking positions for upside price movement.
10:15 EDTDGXRumor: Quest Diagnostics moves up on renewed takeover chatter
Subscribe for More Information
May 21, 2015
08:16 EDTGHDXGenomic Health's Oncotype prostate cancer test issued draft LCD determination
Subscribe for More Information
May 20, 2015
08:08 EDTGHDXGenomic Health's Oncotype prostate cancer risk test shows positive results
Subscribe for More Information
May 19, 2015
09:31 EDTLHORIG3N announces strategic collaboration with LabCorp
Subscribe for More Information
09:18 EDTILMN, QGENBofA/Merrill life sciences analysts hold an analyst/industry conference call
Analysts, along with Nancy J. Kelley, a nationally recognized executive and lawyer who has championed the field of Synthetic/Engineering Biology in the U.S., discuss what Synthetic Biology is and whether it will disrupt the Healthcare landscape and how Synthetic Biologic-based products would be regulated on an Analyst/Industry conference call to be held on May 19 at 2 pm.
07:28 EDTLHUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
May 18, 2015
16:07 EDTILMNIllumina files new patent infringement suit against Roche unit
Subscribe for More Information
08:46 EDTLHLabCorp announces full portfolio of Hep C virus drug resistance assays
LabCorp announced the launch of two new Hepatitis C Virus drug resistance assays. The HCV NS5A and NS5B Drug Resistance Assays expand LabCorp’s portfolio of HCV resistance tests that includes HCV GenoSure NS3/4A, which was launched in 2011. These tests are available through Monogram Biosciences, a member of the LabCorp Specialty Testing Group, and a leader in the development and commercialization of innovative antiviral diagnostics.
08:05 EDTGHDXGenomic Health announces results from study on methods to detect bladder cancer
Genomic Health announced positive results from a second, larger liquid biopsy feasibility study demonstrating the Company's ability to detect tumor-specific DNA in urine, which is expected to enable bladder cancer recurrence monitoring. It is estimated that early-stage bladder cancer recurs in only 10 to 15 percent of patients in the first year, and in more than half of patients over time. However, approximately one-third of all cystoscopies – a procedure using a thin instrument equipped with a camera and light to look at the inside of the bladder – generate false positive results. Genomic Health and its collaborators used the Company's next-generation sequencing and polymerase chain reaction based platforms and refined methodology to target tumor-specific differential DNA methylation and single nucleotide variations. In the study, researchers identified tumor-specific DNA markers in 94 percent of tissue samples and found a strong association between the same markers in urine. These findings are expected to enable accurate monitoring for cancer recurrence in the urine of early-stage bladder cancer patients.
May 15, 2015
11:02 EDTGHDXGenomic Health says Oncotype DX shown to lower overall healthcare costs
Genomic Health announced results from three studies that show the real-world positive impact of the Oncotype DX Genomic Prostate Score and the test's value in managing healthcare costs associated with treatment decisions in low-risk patients. An analysis of the performance of the Oncotype DX GPS in the first 4,000 men tested showed that the test refined patient risk for one in four men across all groups of patients, the company said. In a separate study, researchers analyzed the clinical and economic implications of adding GPS to risk assessment compared to clinical and pathological assessment alone in the management of clinically low-risk prostate cancer. Results showed incorporating GPS into prostate cancer management resulted in a cost reduction of approximately $2,000 per patient in the first three years after diagnosis.
10:28 EDTQGEN, MYGNMAC updates positive for NanoString, Myriad, Invitae, QIAGEN, says Leerink
Leerink said that coverage updates posted yesterday by Medicare Administrative Contractors were favorable for NanoString (NSTG), Myriad Genetics (MYGN), Invitae (NVTA) and QIAGEN (QGEN). The firm has Outperform ratings on NanoString and Invitae and Market Perform rating on the other two stocks listed.
08:31 EDTGHDXGenomic Health announces results from studies of Oncotype DX GPS
Genomic Health announced results from three studies that show the real-world positive impact of the Oncotype DX Genomic Prostate Score and the test's value in managing healthcare costs associated with treatment decisions in low-risk patients. An analysis of the performance of the Oncotype DX GPS in the first 4,000 men tested showed that the test refined patient risk for one in four men across all groups of patients. In a separate study, researchers analyzed Oncotype DX test results from 200 U.S. prostate cancer patients to see how the change in their treatment decision based on the GPS results affected the cost of their treatment. Results showed that immediate treatment costs declined by more than $5,700 per patient. This reduction in costs was associated with increased use of active surveillance from 44 percent to 70 percent of the time. These results indicate that incorporating GPS into treatment decisions can reduce overall healthcare costs within five years. Genomic Health researchers analyzed data compiled from four different Oncotype DX prostate cancer test studies involving 138 African-American patients. Results of this analysis showed that the tumor biology measured by the Oncotype DX GPS was similar between African-American and Caucasian men, reinforcing findings from the second validation study conducted in collaboration with the Uniformed Services University of the Health Sciences' Center for Prostate Disease Research.
08:05 EDTQGENQIAGEN has a conference call hosted by JPMorgan
Subscribe for More Information
07:09 EDTMYGNMyriad Genetics presents clinical data for Prolaris test
Myriad Genetics presented clinical data for its Prolaris test at the 2015 American Urological Association, or AUA, Annual Meeting being held May 15-19 in New Orleans, La. The results highlighted and underscored the significant ability of the Prolaris test to help physicians improve care for men diagnosed with prostate cancer. In this pioneering study, Myriad presented important new clinical validation data that establishes an active surveillance, or AS, threshold for men with localized prostate cancer. Specifically, the AS threshold is a composite of the Prolaris test score and clinicopathologic features. In the validation data featured at AUA, the pre-defined AS threshold was evaluated in 765 conservatively managed men, and the clinical endpoint was 10-year risk of prostate cancer mortality. The results showed that at the AS threshold, the predicted 10-year survival rate of prostate cancer patients was 97%. Conversely, there was a three percent risk of 10-year, prostate-specific mortality. Importantly, however, there were no observed prostate cancer-specific deaths over 10 years among men whose scores fell below the AS threshold. Additionally, a separate analysis of 4,218 patients was performed to determine what percentage of patients who were clinically tested with Prolaris would be candidates for active surveillance based on the validated AS threshold. Of this commercial cohort, 36% qualified for active surveillance based on their clinical features alone. However, when the Prolaris test was added to the clinical risk assessment, 60% of these patients fell below the AS threshold, representing a significant increase in the total number of candidates who may be eligible for active surveillance.
May 13, 2015
18:47 EDTMYGNMyriad Genetics to present data from 19 studies at 2015 ASCO meeting
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use